Impact of transferrin saturation on cardiovascular events in non-dialysis-dependent chronic kidney disease patients treated with darbepoetin alfa. [PDF]
J NephrolNakai K +3 more
europepmc +1 more source
Advancing Anemia Management in Chronic Kidney Disease: Assessing the Superiority of Darbepoetin Alfa Over Erythropoietin Alpha. [PDF]
CureusKhullar D, Muchhala SS, T A.
europepmc +1 more source
Switching Between Epoetins: A Practice in Support of Biosimilar Use [PDF]
, 2016 core +1 more source
Acquired Pure Red Cell Aplasia Following Recombinant Erythropoietin (Darbepoetin-alfa) Therapy. [PDF]
Indian J Nephrol, 2020 Padhi S +5 more
europepmc +1 more source
JR-131, a Biosimilar of Darbepoetin Alfa, for the Treatment of Hemodialysis Patients With Renal Anemia: A Randomized, Double-Blinded, Parallel-Group Phase 3 Study. [PDF]
Ther Apher Dial, 2020 Nishi S +4 more
europepmc +1 more source
Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial.
Clin J Am Soc Nephrol, 2020 Hayashi T +10 more
europepmc +1 more source
Relationship between variations in time-dependent response to erythropoiesis-stimulating agents and mortality in hemodialysis patients: a single-center study [PDF]
, 2016 KATAOKA Hiroshi +7 more
core +2 more sources
Long-Term Safety and Efficacy of JR-131, a Biosimilar of Darbepoetin Alfa, in Japanese Patients With Renal Anemia Undergoing Hemodialysis: Phase 3 Prospective Study. [PDF]
Ther Apher Dial, 2020 Nishi S +4 more
europepmc +1 more source